MG
ACET icon

Michael Gelband’s Adicet Bio ACET Stock Holding History

Michael Gelband’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,456
Closed -$134K – 1799
2023
Q1 		$134K Buy
+1,456
New +$183K ﹤0.01% 1609
2021
Q2 		– Sell
-4,480
Closed -$938K – 2274
2021
Q1 		$938K Buy
4,480
+1,516
+51% +$348K 0.01% 952
2020
Q4 		$666K Buy
+2,964
New +$607K 0.01% 1077

Other funds holding ACET

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Michael Gelband's ACET Position: Q2 2023 in Review

Michael Gelband sold out of Adicet Bio (ACET) in Q2 2023, closing a stake of 1,456 shares — an estimated $134K sold.

Michael Gelband first reported a position in ACET in Q4 2020 and held it in 3 quarters. The position peaked at $938K in Q1 2021. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

  • Michael Gelband reported no remaining Adicet Bio position as of Q2 2023 after selling out during the quarter.
  • Michael Gelband sold 1,456 Adicet Bio shares in Q2 2023, an estimated $134K.
  • Michael Gelband first reported a position in Adicet Bio in Q4 2020 and held it in 3 quarters.
  • Michael Gelband's Adicet Bio position peaked at $938K in Q1 2021.
  • 94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.